ArticleArthritis research & therapy2025
Clinical and molecular links between chronic systemic inflammation and structural damage in axial spondyloarthritis.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Observational
- Hearing impairment in patients with axial spondyloarthritis: association with chronic inflammatory burden and neurobiological proteins.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundStructural damage in axial spondyloarthritis (axSpA) is closely linked to chronic inflammation, yet the underlying mechanisms remain incompletely understood. For that reason, we investigated the relationship between persistent systemic inflammation and radiographic damage in axSpA and characterized the associated molecular and cellular pathways.
methodsA retrospective registry of 238 axSpA patients was stratified by C-reactive protein (CRP) trajectory over the last 5 years into non-persistent, intermediate, and persistent inflammation groups. Radiographic damage, serum bone metabolism markers, and proteomic profiles (Olink 184-protein panel) were assessed. In vitro assays in SaOS-2 osteoblast-like cells evaluated functional responses to CDCP1, CRP, and patient serum.
resultsPersistent inflammation was observed in 25.2% of patients and was independently associated with greater radiographic damage, including higher total and lumbar mSASSS scores and syndesmophyte counts. Proteomic analysis revealed a distinct inflammatory signature in persistently inflamed patients, marked by elevated levels of MMP9, IL-6, CDCP1, and neutrophil-related proteins. CDCP1 strongly correlated with radiographic damage and bone turnover markers. Functional assays showed that CDCP1 and CRP modulate osteoblast gene expression, promoting osteogenic and inflammatory pathways in a dose-dependent manner. Moreover, serum from persistently inflamed axSpA patients induced osteogenic remodeling in vitro.
conclusionPersistent systemic inflammation in axSpA is a key independent driver of structural damage and is linked to a distinct proteomic and functional signature involving neutrophil activation and bone remodeling. CDCP1 may serve as a potential biomarker and mediator of inflammation-driven osteoproliferation in axSpA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.